However, when we examined FSCN1 expression in a series of human primary prostate cancer (n = 52), fusion-positive (n = 32) or fusion-negative (n = 20) and normal prostate tissues (n = 20), we observed that no significant differences between these groups of samples (Supplementary Fig. S1b) and no correlation with the ERG transcription factor status. Here, FSCN1 is linked to prostate cancer.